loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Imeglimin

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Imeglimin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 163Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Poxel Reports Q2 And H1 2024 Revenue, Provides Corporate Update
    Poxel Reports Q2 And H1 2024 Revenue, Provides Corporate Update

    09 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240908901962/en

    BUSINESSWIRE
    09 Sep 2024
    Share Share
    Poxel Updates Q2 Financials Reschedules Annual General Meeting
    Poxel Updates Q2 Financials Reschedules Annual General Meeting

    15 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240714885795/en

    BUSINESSWIRE
    15 Jul 2024
    Share Share
    Poxel to Report Its 2023 Annual Results by the End of April 2024
    Poxel to Report Its 2023 Annual Results by the End of April 2024

    28 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240328548115/en

    BUSINESSWIRE
    28 Mar 2024
    Share Share
    Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA
    Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA

    03 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221002005044/en

    BUSINESSWIRE
    03 Oct 2022
    Share Share
    Poxel Reports Financial Results for First Half 2022 & Provides Corporate Update
    Poxel Reports Financial Results for First Half 2022 & Provides Corporate Update

    21 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220920006290/en

    BUSINESSWIRE
    21 Sep 2022
    Share Share
    IMEGLIMIN with Novell Process IMEGLIMIN
    IMEGLIMIN with Novell Process IMEGLIMIN

    22 Aug 2022

    // PRESS RELEASE

    https://virujgroup.com/imeglimin/

    PRESS RELEASE
    22 Aug 2022
    Share Share